Skip to main content

Advertisement

SpringerLink
Log in

A clinical comparative study of GP and TP 1st-line chemotherapies for advanced non-small cell lung cancer

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of the study was to evaluate the efficacies of initial gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) 1st-line chemotherapies for advanced non-small cell lung cancer (NSCLC) and observe their side effects.

Methods

Eighty-one cases were randomly divided into two groups: GP group and TP group. In GP group, administered gemcitabine (GEM) 1000 mg/m2 on days 1 and 8; i.v. cisplatin (DDP) 30 mg/m2 from days 2 to 4 on a 28-day cycle. In TP group, administered paclitaxel (PTX) 175 mg/m2 on day 1, i.v. DDP 30 mg/m2 from days 2 to 4 on a 28-day cycle.

Results

GP group had an overall response rate (ORR; CR+PR) of 45.0% (18/40). TP had an overall response rate of 43.2% (16/37). Short-term ORR had no significant difference between two groups (χ2 = 0.527, P = 0.957). GP had median survival time of 11 months and 37.7% of one-year survival rate, while TP showed 11 months of median survival time and 31.7% of one-year survival rate. Survival had no significant difference between two groups (χ2 = 0.140, P = 0.708). However, main side effects varied. Thrombocytopenia of GP group was significantly more than that of TP group, while peripheral neuritis, nausea/vomiting and myalgia of TP group were significantly more than those of GP group.

Conclusion

Both GP and TP regimens had no significant difference in short-term treatment effect and survival rate for initial treatment of advanced NSCLC. However, side effects related to GP regimen treatment were slighter. Therefore, it was considered as the preferred initial first-line treatment for NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Similar content being viewed by others

References

  1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 2002, 346: 92–98.

    Article  CAS  PubMed  Google Scholar 

  2. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol, 2002, 20: 4285–4291.

    Article  CAS  PubMed  Google Scholar 

  3. Jiang T, Xiong HQ, Tang XK, et al. A clinical study on efficacy of gemcitabine and carboplatin versus paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. Chin J Lung Cancer (Chinese), 2003, 6: 89–91.

    Google Scholar 

  4. Zheng J, Bai H, Ye JZ, et al. The clinical observation of gemcitabine or paclitaxel combined with cisplatin in the treatment of advanced patients with non-small cell lung cancer. Chin Clin Oncol (Chinese), 2003, 8: 263–265.

    Google Scholar 

  5. Zhou H, Tang M, Shi L. Comparison of paclitaxel plus cisplatin vs gemcitabine and cisplatin treatments for advanced non-small cell lung cancer. Guangdong Med J (Chinese), 2006, 27: 1389–1391.

    Google Scholar 

  6. Sun Y, Zhou JC. Medical oncology. 4th edition. Beijing: Beijing People’s Medical Publishing House, 2004. 106–107.

    Google Scholar 

  7. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys, 2000, 47: 13–47.

    Article  CAS  PubMed  Google Scholar 

  8. Sun Y. Anticancer drugs. 1st edition. Beijing: Peking University Medial Press, 2006. 135–138.

    Google Scholar 

  9. Cheng XM, Wang HM, Yu Y, et al. Combination of gemcitabine and carboplatin in the treatment of patients with non-small cell lung cancer. Cancer Res Prev Treat (Chinese), 2006, 33: 442–443.

    CAS  Google Scholar 

  10. Su W, Cao H, Wang Y. Gemcitabine plus cisplatin combination in treatment of elderly patients with advanced cancer. Cancer Res Prev Treat (Chinese), 2008, 35: 355–357.

    CAS  Google Scholar 

  11. Zhang AQ, Guo GF. Advanced non-small cell lung cancer treatment with vinorelbine, docetaxel, gemcitabine combined with cisplatin, respectively: a report of 95 patients. Tumor (Chinese), 2002, 22: 152–153.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, The Affiliated North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu, 062552, China

    Kun Chen, Qiang Lin, Chunlin Chang, Yannan Zhao, Yue’e Liu, Na Wang, Huiling Su & Yuehua Huang

Authors
  1. Kun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiang Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chunlin Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yannan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yue’e Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Na Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Huiling Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuehua Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiang Lin.

Additional information

Supported by a grant of Science and Technology Department of Hebei Province (No. 072761711).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, K., Lin, Q., Chang, C. et al. A clinical comparative study of GP and TP 1st-line chemotherapies for advanced non-small cell lung cancer. Chin. -Ger. J. Clin. Oncol. 9, 621–624 (2010). https://doi.org/10.1007/s10330-010-0690-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-010-0690-6

Key words

Search

Navigation